RCM
RA Capital Management Portfolio holdings
AUM
$5.94B
This Quarter Return
+31.2%
1 Year Return
+18.15%
3 Year Return
+417.5%
5 Year Return
+458.13%
10 Year Return
+21,247.51%
AUM
$4.93B
AUM Growth
+$4.93B
(+5.2%)
Cap. Flow
-$240M
Cap. Flow
% of AUM
-4.87%
Top 10 Holdings %
Top 10 Hldgs %
50.68%
Holding
90
New
9
Increased
17
Reduced
11
Closed
20
Top Buys
| 1 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$95M |
| 2 |
Vor Biopharma
VOR
|
$77.3M |
| 3 |
Avidity Biosciences
RNA
|
$72.9M |
| 4 |
Vaxcyte
PCVX
|
$61.2M |
| 5 |
Acrivon Therapeutics
ACRV
|
$55.4M |
Top Sells
| 1 |
FMTX
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
|
$180M |
| 2 |
Biogen
BIIB
|
$112M |
| 3 |
Ascendis Pharma
ASND
|
$74.6M |
| 4 |
Relmada Therapeutics
RLMD
|
$74M |
| 5 |
Solid Biosciences
SLDB
|
$48.1M |
Sector Composition
| 1 | Healthcare | 99.36% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Acrivon Therapeutics
ACRV
$42.8M
| $55.4M | 1.12% |
+4,810,508
| New | +$55.4M |
|
27
Tyra Biosciences
TYRA
$667M
| $55M | 1.12% |
7,236,454
| – | – |
|
28
Acumen Pharmaceuticals
ABOS
$81.8M
| $52.8M | 1.07% |
9,770,773
| – | – |
|
29
Akero Therapeutics
AKRO
$3.61B
| $52.6M | 1.07% |
958,980
| – | – |
|
|
CLYM
30
Climb Bio, Inc. Common Stock
CLYM
$157M
| $48.3M | 0.98% |
13,150,849
| – | – |
|
31
GH Research
GHRS
$863M
| $47.6M | 0.97% |
4,898,373
| – | – |
|
|
ICVX
32
DELISTED
Icosavax, Inc. Common Stock
ICVX
| $47.4M | 0.96% |
5,963,565
| – | – |
|
33
Rocket Pharmaceuticals
RCKT
$347M
| $47.1M | 0.96% |
2,407,149
+300,000
| +14% | +$5.87M |
|
34
Nkarta
NKTX
$150M
| $46.8M | 0.95% |
7,805,129
| – | – |
|
35
NewAmsterdam Pharma
NAMS
$2.81B
| $43.6M | 0.88% |
+4,000,000
| New | +$43.6M |
|
36
RxSight
RXST
$354M
| $38.7M | 0.78% |
3,052,796
| – | – |
|
37
AN2 Therapeutics
ANTX
$31.2M
| $36M | 0.73% |
3,773,517
| – | – |
|
|
ALPN
38
DELISTED
Alpine Immune Sciences, Inc. Common Stock
ALPN
| $32.3M | 0.66% |
4,397,368
+40,736
| +0.9% | +$299K |
|
39
Geron
GERN
$912M
| $31.3M | 0.63% |
12,930,711
-17,195,588
| -57% | -$41.6M |
|
40
Design Therapeutics
DSGN
$327M
| $30.5M | 0.62% |
2,971,231
+198,000
| +7% | +$2.03M |
|
41
HilleVax
HLVX
$105M
| $29.4M | 0.6% |
1,760,019
| – | – |
|
|
KNTE
42
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $26M | 0.53% |
4,264,144
| – | – |
|
43
Viridian Therapeutics
VRDN
$1.58B
| $25.7M | 0.52% |
880,000
| – | – |
|
44
ARS Pharmaceuticals
SPRY
$1.08B
| $25.7M | 0.52% |
+3,009,678
| New | +$25.7M |
|
45
Celcuity
CELC
$2.25B
| $19.6M | 0.4% |
+1,400,001
| New | +$19.6M |
|
|
46
Solid Biosciences
SLDB
$429M
| $18.4M | 0.37% |
3,426,286
-8,941,587
| -72% | -$48.1M |
|
|
DALS
47
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15M | 0.3% |
1,500,000
| – | – |
|
48
scPharmaceuticals
SCPH
$297M
| $13.3M | 0.27% |
+1,856,904
| New | +$13.3M |
|
49
Enliven Therapeutics
ELVN
$1.22B
| $13.3M | 0.27% |
+3,250,724
| New | +$13.3M |
|
50
Tenaya Therapeutics
TNYA
$184M
| $12.2M | 0.25% |
6,067,483
+4,465,474
| +279% | +$8.98M |
|